20161222-next-investor-events
Category: 2016
UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb
UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb
Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting
20161114-poster-hbv_aasld-en
Successful Completion of Transgene’s Rights Issue – Gross proceeds of circa €46.4 million
20161110 – TRANSGENE- Results PR
Transgene Announces Publication in OncoImmunology of Pre-Clinical Data Demonstrating Delivery of a Fully Functional Immune Checkpoint Inhibitor (ICI) with Anti-Tumor Efficacy by a New Generation of Oncolytic Viral Immunotherapy
Publication OncoImmunology
Transgene Reports Third Quarter 2016 Financial Results
20161020-q3-financial-en
Transgene Announces Rights Issue
20161020 – Capital increase EN FINAL
First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
20161017-tg1050-md-us-final
Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
alliance_transgene-collab-press-release_row
Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines
20161005-ov-vancouver-vacv-antibody-poster-final-us
